- Accessible protein design for wet labs
- Concentrates on drug discovery depth over broad coverage
- Scales to organization-wide healthcare rollouts
Cradle
AI protein design for wet labs
SF7.5
SF Score editorial score across features, ease, and value, based on public reviews and product research. Learn more →
Support protein engineering programsProtein engineering and biotech teams
Support protein engineering programsProtein engineering and biotech teams
Best for
Protein engineering and biotech teams
Pricing
Custom
SoftFinders Score
7.5 / 10
Overview
What is Cradle?
Cradle is an AI protein engineering platform that helps scientists design and optimize proteins for biotech research programs. The product is positioned around R&D acceleration and computational biology rather than guaranteed clinical outcomes, and engagement typically happens through pharma partnerships rather than self-serve subscription buying. Buyers should weigh data access requirements, expected timelines to validated leads, and the cost structure across collaborations before committing to a long discovery program today.
Cradle works best for protein engineering and biotech teams, and its edge is accessible protein design for wet labs. The honest trade-off here: best value needs in-house protein programs. Pricing is sales-led and scoped per buyer rather than posted publicly. Run a small pilot to confirm fit before committing to a wider rollout.
KEY FEATURES
What you get out of the box
Target Discovery
Identifies potential drug targets from biological data
Molecule Design
Generates and ranks small molecule candidates
Protein Modeling
Predicts and designs protein structures
Knowledge Graph
Connects biological and chemical knowledge sources
Virtual Screening
Screens compound libraries against targets
Literature Intelligence
Mines biomedical literature for relevant evidence
USE CASES
Where teams put it to work
Support protein engineering programs
Mine literature for research signals
Run virtual screens against targets
Collaborate with pharma partners
Bridge AI design and wet lab cycles
Identify drug targets from biology data
Editorial Take
What we like, and what to verify
- Best value needs in-house protein programs
- Drug success still depends on downstream trials
- Pricing is sales-led and needs scoping upfront
Screenshots
A look inside
Alternatives
Tools to consider next
Iktos SF 7.4
Why consider it
Generative chemistry and synthesis planning AI
Chai Discovery SF 7.3
Why consider it
Molecular structure prediction for discovery research
NOETIK SF 7.1
Why consider it
Spatial biology models for cancer targets
Generate Biomedicines SF 7.7
Why consider it
Generative protein design across modalities
Causaly SF 7.6
Why consider it
Biomedical evidence and reasoning for R&D
Schrödinger SF 8
Why consider it
Physics-based and ML molecular simulation
FAQ